Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background— Experimental interleukin-1 receptor antagonist gene overexpression has shown that interleukin-1 receptor antagonist is cardioprotective during global cardiac ischemia. The aim of the present study was to test the impact of an exogenous recombinant human interleukin-1 receptor antagonist (anakinra) in experimental acute myocardial infarction. Methods and Results— Two animal studies were conducted: one of immediate anakinra administration during ischemia in the mouse and one of delayed anakinra administration 24 hours after ischemia in the rat. Seventy-eight Institute of Cancer Research mice and 20 Wistar rats underwent surgical coronary artery ligation (or sham operation) and were treated with either anakinra 1 mg/kg or NaCl 0.9% (saline). Treatment was administered during surgery and then daily for 6 doses in the mice and starting on day 2 daily for 5 doses in the rats. Twenty-eight mice underwent infarct size assessment 24 hours after surgery, 6 saline-treated mice and 22 mice treated with increasing doses of anakinra (1 mg/kg [n=6], 10 mg/kg [n=6], and 100 mg/kg [n=10]); 6 mice were euthanized at 7 days for protein expression analysis. The remaining animals underwent transthoracic echocardiography before surgery and 7 days later just before death. Cardiomyocyte apoptosis was measured in the peri-infarct regions. The antiapoptotic effect of anakinra was tested in a primary rat cardiomyocyte culture during simulated ischemia and in vitro on caspase-1 and -9 activities. At 7 days, 15 of the 16 mice (94%) treated with anakinra were alive versus 11 of the 20 mice (55%) treated with saline ( P =0.013). No differences in infarct size at 24 hours compared with saline were observed with the 1- and 10-mg/kg doses, whereas a 13% reduction in infarct size was found with the 100-mg/kg dose ( P =0.015). Treatment with anakinra was associated with a significant reduction in cardiomyocyte apoptosis in both the immediate and delayed treatment groups (3.1±0.2% versus 0.5±0.3% [ P <0.001] and 4.2±0.4% versus 1.1±0.2% [ P <0.001], respectively). Compared with saline-treated animals, anakinra-treated mice and rats showed signs of more favorable ventricular remodeling. In vitro, anakinra significantly prevented apoptosis induced by simulated ischemia and inhibited caspase-1 and -9 activities. Conclusions— Administration of anakinra within 24 hours of acute myocardial infarction significantly ameliorates the remodeling process by inhibiting cardiomyocyte apoptosis in 2 different experimental animal models of AMI. This may open the door for using anakinra to prevent postischemic cardiac remodeling and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,121
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Caspases: the executioners of apoptosis
COHEN, G. M. (1997) · Biochemical Journal · doi:10.1042/bj3260001 · Cited by 4,719
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Tei, C., Ling, L. H., Hodge, D. O., Bailey, K. R., Oh, J. K., Rodeheffer, R. J., Tajik, A. J., & Seward, J. B. (1995) · PubMed · Cited by 1,547
Claycomb, W. C., Lanson, N. A., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., & Izzo, N. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2979 · Cited by 1,546
Ducharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E., Schoen, F. J., Kelly, R. A., Werb, Z., Libby, P., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8768 · Cited by 808
Creemers, E. E. J. M., Cleutjens, J. P. M., Smits, J. F. M., & Daemen, M. J. A. P. (2001) · Circulation Research · doi:10.1161/hh1501.094396 · Cited by 598
Dinarello, C. A. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00023-3 · Cited by 582
Biasucci, L. M., Liuzzo, G., Fantuzzi, G., Caligiuri, G., Rebuzzi, A. G., Ginnetti, F., Dinarello, C. A., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.16.2079 · Cited by 485
Self-citation
Cited by
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
The inflammatory response in myocardial injury, repair, and remodelling
Frangogiannis, N. G. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.28 · Cited by 1,738
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
“There are also preclinical studies demonstrating that blockade of IL-1β is effective (59, 60) and clinical trials using anakinra have revealed that blockade of IL-1 is effective in reducing post infarction remodeling (61, 62) as well as increased exercise tolerance (63).”
BackgroundOng, S.-B., Hernández-Reséndiz, S., Crespo-Avilan, G. E., Mukhametshina, R. T., Kwek, X.-Y., Cabrera-Fuentes, H. A., & Hausenloy, D. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.001 · Cited by 918
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Self-citationThe NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Self-citationPathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy
Turer, A. T., & Hill, J. A. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.032 · Cited by 634
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., Kannan, H. R., Menna, A. C., Voelkel, N. F., & Abbate, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108586108 · Cited by 629
Self-citationPathophysiology of Heart Failure
Tanai, E., & Frantz, S. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140055 · Cited by 552
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction
Westman, P. C., Lipinski, M. J., Luger, D., Waksman, R., Bonow, R. O., Wu, E., & Epstein, S. E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.073 · Cited by 506
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Hanna, A., & Frangogiannis, N. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07071-0 · Cited by 418
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Self-citationNlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., Al-Dabet, M. M., Ranjan, S., Wolter, J., Wacker, C., et al. (2015) · Kidney International · doi:10.1038/ki.2014.271 · Cited by 411
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Self-citationAbbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Self-citationInflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury
Toldo, S., Mauro, A. G., Cutter, Z., & Abbate, A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00158.2018 · Cited by 369
Self-citationErratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.33 · Cited by 363
Modulation of inflammation by autophagy: Consequences for human disease
Netea-Maier, R. T., Plantinga, T. S., van de Veerdonk, F. L., Smit, J. W., & Netea, M. G. (2016) · Autophagy · doi:10.1080/15548627.2015.1071759 · Cited by 349
“IL1RN also has intracellular effects, and cellular uptake of IL1RN has been reported.(75) Therefore, IL1RN might influence LAP through several possible mechanisms: i) direct inhibition of IL1 bioactivity, ii) intracellular interaction with the LAP machinery or iii) indirectly via effects on other processes such as inf…”
BackgroundMacrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
van Hout, G. P. J., Bosch, L., Ellenbroek, G. H. J. M., de Haan, J. J., van Solinge, W. W., Cooper, M. A., Arslan, F., de Jager, S. C. A., Robertson, A. A. B., Pasterkamp, G., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw247 · Cited by 331
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Self-citationRole of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
The role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Self-citationAbbate, A., Trankle, C. R., Buckley, L. F., Lipinski, M. J., Appleton, D., Kadariya, D., Canada, J. M., Carbone, S., Roberts, C. S., Abouzaki, N., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014941 · Cited by 300
Self-citationSeropian, I. M., Toldo, S., Van Tassell, B. W., & Abbate, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.014 · Cited by 296
Self-citationAnti‐inflammatory therapies in myocardial infarction: failures, hopes and challenges
Huang, S., & Frangogiannis, N. G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14155 · Cited by 282
Sensing damage by the NLRP3 inflammasome
Leemans, J. C., Cassel, S. L., & Sutterwala, F. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01043.x · Cited by 281
“Experimental studies in mice and rats also showed that anakinra, a recombinant IL-1R antagonist, is able to improve cardiac remodelling after acute myocardial infarction by inhibiting cardiomyocyte apoptosis (55, 56).”
Interleukin-18, more than a Th1 cytokine
Novick, D., Kim, S., Kaplanski, G., & Dinarello, C. A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.014 · Cited by 280
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“among patients with heart failure.(59,60) Further, recent findings”
BackgroundIL‐1: Discoveries, controversies and future directions
Dinarello, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040319 · Cited by 268
Immune Cells and Immunotherapy for Cardiac Injury and Repair
Rurik, J. G., Aghajanian, H., & Epstein, J. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318005 · Cited by 265
Postischemic Revascularization: From Cellular and Molecular Mechanisms to Clinical Applications
Silvestre, J.-S., Smadja, D. M., & Lévy, B. I. (2013) · Physiological Reviews · doi:10.1152/physrev.00006.2013 · Cited by 255
Saxena, A., Chen, W., Su, Y., Rai, V., Uche, O. U., Li, N., & Frangogiannis, N. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300725 · Cited by 252
Hoegen, T., Tremel, N., Klein, M., Angele, B., Wagner, H., Kirschning, C., Pfister, H.-W., Fontana, A., Hammerschmidt, S., & Koedel, U. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100790 · Cited by 211
Hilgendorf, I., Frantz, S., & Frangogiannis, N. G. (2024) · Circulation Research · doi:10.1161/circresaha.124.323658 · Cited by 180
“148 Pharmacological targeting of IL-1 cascades also showed protective effects in experimental models of MI, attenuating adverse remodeling, 149 reducing cardiomyocyte apoptosis, 150 and suppressing arrhythmogenesis.”
Audia, J. P., Yang, X.-M., Crockett, E. S., Housley, N., Haq, E. U., O’Donnell, K., Cohen, M. V., Downey, J. M., & Alvarez, D. F. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-018-0692-z · Cited by 178
Johnston, W. F., Salmon, M., Su, G., Lu, G., Stone, M. L., Zhao, Y., Owens, G. K., Upchurch, G. R., & Ailawadi, G. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300432 · Cited by 170
“study and has been similarly shown by other groups evaluating anakinra in murine models.(20,44) As anakinra is recombinant human IL-1R antagonist, there may be a decreased specificity for mouse IL-1R that may explain the need for higher doses.”
ResultPerman, J. C., Boström, P., Lindbom, M., Lidberg, U., StÅhlman, M., Hägg, D., Lindskog, H., Scharin Täng, M., Omerovic, E., Mattsson Hultén, L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43068 · Cited by 168
Yan, X., Shichita, T., Katsumata, Y., Matsuhashi, T., Ito, H., Ito, K., Anzai, A., Endo, J., Tamura, Y., Kimura, K., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.004408 · Cited by 164
“an IL-1 receptor blocker alleviated LV remodeling without affecting early infarct size.(39) These findings suggested that the cardioprotective effect of an IL-1 receptor blocker is at least in”
BackgroundMarchetti, C., Toldo, S., Chojnacki, J., Mezzaroma, E., Liu, K., Salloum, F. N., Nordio, A., Carbone, S., Mauro, A. G., Das, A., et al. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000247 · Cited by 161
Self-citationAbbate, A., Kontos, M. C., Abouzaki, N. A., Melchior, R. D., Thomas, C., Van Tassell, B. W., Oddi, C., Carbone, S., Trankle, C. R., Roberts, C. S., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.003 · Cited by 160
Self-citationIkonomidis, I., Tzortzis, S., Andreadou, I., Paraskevaidis, I., Katseli, C., Katsimbri, P., Pavlidis, G., Parissis, J., Kremastinos, D., Anastasiou-Nana, M., et al. (2014) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.113.001193 · Cited by 160
“Anakinra has been shown to reduce experimental myocardial infarction through inhibition of apoptosis and to improve LV volumes after myocardial infarction.(7,8) Enhanced intracellular IL-1 receptor antagonist synthesis is found at 3 hours of ischemia and protects cardiomyocytes from hypoxia-induced death through reduc…”
BackgroundThe role of the inflammasome in nonmyeloid cells
Yazdi, A. S., Drexler, S. K., & Tschopp, J. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9437-y · Cited by 76
“In both cases, the authors argue that inhibiting inflammation through IL-1RA leads to a reduction of cardiomyocyte apoptosis, thereby allowing accelerated recovery.”
BackgroundLi, C., Ma, Z., Wei, X., Wang, Y., Wu, J., Li, X., Sun, X., Ding, Z., Yang, C., & Zou, Y. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10577-9 · Cited by 13
“Then Anakinra, a recombinant human interleukin-1 receptor (IL-1R) antagonist [72], was applied to cardiomyocytes that were treated with the cultured medium of H/R-induced macrophages.”
Metadata
- Authors
- Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. L., Houser, J.-E., Qureshi, I. Z., Ownby, E. D., Gustini, E., Biasucci, L. M., Severino, A., Capogrossi, M. C., Vetrovec, G. W., Crea, F., Baldi, A., Kukreja, R. C., & Dobrina, A.
- Venue
- Circulation
- Published
- 2008-05-20
- Volume
- 117
- Issue
- 20
- Pages
- 2670-2683
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2074130375
- Cited by
- 360
- References
- 40
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.